BIOMAT Database Logo BIOMAT Database Logo

Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients. 1996

L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Institute of Endocrinology, Catholic University School of Medicine, Rome, Italy.

In order to gain insight into the neuroendocrine mechanism underlying the paradoxical GH response to TRH in acromegalic patients, we have investigated the effect of an infusion of Naloxone (Nal, 1.6 mg/hr for two hours), on a TRH test performed both in responder (n = 9) and non-responder (n = 5) acromegalic patients. The response of GH, PRL and TSH to TRH injection were evaluated. NAL did not exert significant variations in the GH response, even if different patterns of GH response during NAL were observed in the group of TRH-responder patients. Similarly, TRH-induced PRL response was not significantly affected by the infusion of an opiate antagonist. On the contrary, a significant inhibition of the TSH response was observed in the group of TRH-responder patients (delta TSH after TRH 4.76 +/- 1.11 microU/ml, after NAL + TRH 2.81 +/- 0.99 microU/ml, p < 0.05). No significant effects were observed in the TRH non-responder patients (delta TSH after TRH 4.58 +/- 1.44 microU/ml, after NAL + TRH 6.26 +/- 3.27 microU/ml). The differences observed in the two groups of patients could be ascribed to a different endogenous somatostatinergic tone and could furnish a prognostic indication in acromegalic patients.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
The influence of diabetes mellitus on thyrotropin response to thyrotropin-releasing hormone in untreated acromegalic patients.
April 1988, Journal of endocrinological investigation,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Growth hormone response to thyrotropin-releasing hormone in acromegalic patients: reproducibility and dose-response study.
January 1992, Hormone research,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Thyrotropin, prolactin and growth hormone response to synthetic thyrotropin-releasing hormone in newborn infants.
January 1978, Biology of the neonate,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Growth hormone and prolactin response to thyrotropin releasing hormone and growth hormone releasing factor in the immature turkey.
January 1984, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Bovine prolactin, growth hormone, thyroxine and corticoid response to thyrotropin releasing hormone.
February 1973, Endocrinology,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
May 1989, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Effect of somatostatin on thyrotropin, prolactin, growth hormone and insulin responses to thyrotropin releasing hormone and arginine in healthy, hypothyroid and acromegalic subjects.
September 1977, Canadian Medical Association journal,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Serum prolactin and growth hormone response to thyrotropin releasing hormone in prepubertal heifers.
March 1976, Journal of animal science,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Plasma growth hormone response to growth hormone-releasing factor in acromegalic patients.
January 1984, The Journal of clinical endocrinology and metabolism,
L De Marinis, and A Mancini, and P Zuppi, and C Fiumara, and G Conte, and L Sammartano, and M L Fabrizi, and D Valle
Growth hormone response to thyrotropin-releasing hormone in cancer patients.
August 1980, Endocrinologia japonica,
Copied contents to your clipboard!